Thus, there is a biologic rationale supporting the hypothesis that KRAS-mutant NSCLC are intrinsically resistant to EGFR TKIs because of a constitutive activation of the kinase that regulates EGFR signaling (24–27). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.